ELOX insider filings

Eloxx Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-21. Screen ELOX transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Germano Geno J — Director2——1

Recent insider filings — Eloxx Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2026-10-214Germano Geno J — DirectorGrant/award (A): 13,587 (derivative) @ $0EDGAR
2026-10-213Germano Geno J — DirectorHoldings only — no transactions reportedEDGAR
2026-06-174Domicilium Real Estate Fund III LP — 10% ownerOther (J): 238,422 · Other (J): 361,578 · Other (J): 238,422 (derivative) · Other (J): 361,578 (derivative)EDGAR
2026-06-104Webster Stephen W — DirectorGrant/award (A): 13,587 (derivative) @ $0EDGAR
2026-06-104Walts Alan Edmund — DirectorGrant/award (A): 8,590 (derivative) @ $0EDGAR
2026-06-104Aggarwal Sumit — President and CEO, DirectorGrant/award (A): 328,833 (derivative) @ $0EDGAR
2026-06-104Kjellson Nina S — DirectorGrant/award (A): 13,587 (derivative) @ $0EDGAR
2026-06-104Rubin Steven D — DirectorGrant/award (A): 4,018 (derivative) @ $0EDGAR
2026-06-054Domicilium Real Estate Fund III LP — 10% ownerOther (J): 113,636 @ $0 · Other (J): 113,636 (derivative)EDGAR
2026-05-294Coastlands Capital LP — 10% ownerOther (J): 1,250,000 @ $0 · Other (J): 1,250,000 (derivative) @ $0EDGAR
2026-05-084Rubin Steven D — DirectorOption exercise (M): 1,875 · Grant/award (A): 179,854 (derivative) @ $0 · Option exercise (M): 1,875 (derivative) @ $0EDGAR
2026-05-084Aggarwal Sumit — President and CEO, Director, 10% ownerOption exercise (M): 196,880 @ $0.00 · Grant/award (A): 1,000,000 @ $0 · Option exercise (M): 15,000 · Option exercise (M): 260,946 @ $0.15 · Grant/award (A): 42,790 (derivative) @ $0 · Disposition to issuer (D): 42,790 (derivative) · +14 moreEDGAR
2026-05-084Walts Alan Edmund — DirectorOption exercise (M): 1,875 · Grant/award (A): 395,680 (derivative) @ $0 · Option exercise (M): 1,875 (derivative) @ $0EDGAR
2025-01-284Aggarwal Sumit — DirectorOption exercise (M): 30,000 @ $0 · Option exercise (M): 30,000 (derivative) @ $0EDGAR
2025-01-284Rubin Steven D — DirectorOption exercise (M): 3,750 @ $0 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2025-01-284Androski Lindsay — DirectorOption exercise (M): 3,750 @ $0 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2025-01-284Walts Alan Edmund — DirectorOption exercise (M): 3,750 @ $0 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2024-10-174Walts Alan Edmund — DirectorGrant/award (A): 12,000 @ $0EDGAR
2024-10-174Androski Lindsay — DirectorGrant/award (A): 12,000 @ $0EDGAR
2024-10-174Rubin Steven D — DirectorGrant/award (A): 12,000 @ $0EDGAR
2024-10-174Aggarwal Sumit — PRESIDENT AND CEO, DirectorGrant/award (A): 165,000 @ $0EDGAR
2024-01-264Walts Alan Edmund — DirectorGrant/award (A): 7,500 (derivative) @ $0EDGAR
2024-01-264Rubin Steven D — DirectorGrant/award (A): 7,500 (derivative) @ $0EDGAR
2024-01-264Androski Lindsay — DirectorGrant/award (A): 7,500 (derivative) @ $0EDGAR
2024-01-264Aggarwal Sumit — PRESIDENT AND CEO, DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2023-01-314Walts Alan Edmund — DirectorGrant/award (A): 2,859 (derivative) @ $0EDGAR
2023-01-314Rubin Steven D — DirectorGrant/award (A): 2,859 (derivative) @ $0EDGAR
2023-01-314Kariv Tomer — DirectorGrant/award (A): 2,859 (derivative) @ $0EDGAR
2023-01-314Androski Lindsay — DirectorGrant/award (A): 2,859 (derivative) @ $0EDGAR
2023-01-274Aggarwal Sumit — PRESIDENT AND CEO, DirectorGrant/award (A): 68,700 (derivative) @ $0EDGAR
2023-01-274MODUR VIJAY — HEAD OF R&DGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-07-064Androski Lindsay — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2022-06-174Walts Alan Edmund — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-174Veinrib Gadi — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-174Seehra Jasbir — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-174Rubin Steven D — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-174PAREKH RAJESH B — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-174Nussbaum Ran — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-174Kariv Tomer — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-174Avnur Zafrira — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2021-12-034Walts Alan Edmund — DirectorOption exercise (M): 37,695 @ $0 · Option exercise (M): 37,695 (derivative) @ $0EDGAR
2021-12-034Aggarwal Sumit — PRESIDENT AND CEO, DirectorOption exercise (M): 279,158 @ $0 · Tax withholding (F): 81,933 @ $0.72 · Option exercise (M): 279,158 (derivative) @ $0EDGAR
2021-12-034MODUR VIJAY — HEAD OF R&DOption exercise (M): 219,326 @ $0 · Tax withholding (F): 64,373 @ $0.72 · Option exercise (M): 219,326 (derivative) @ $0EDGAR
2021-12-014Geffken Daniel E. — INTERIM CFOPurchase (P): 50,000 @ $0.72EDGAR
2021-07-304Belloff Neil S. — COO, GENERAL COUNSEL &CORP SECOption exercise (M): 1,563 @ $0 · Tax withholding (F): 459 @ $1.32 · Option exercise (M): 1,563 (derivative) @ $0EDGAR
2021-05-264Belloff Neil S. — COO, GENERAL COUNSEL &CORP SECOption exercise (M): 6,250 @ $0 · Tax withholding (F): 1,835 @ $1.39 · Option exercise (M): 6,250 (derivative) @ $0EDGAR
2021-05-204Kariv Tomer — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2021-05-204Veinrib Gadi — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2021-05-204Seehra Jasbir — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2021-05-204Rubin Steven D — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR

Recent 8-K events — Eloxx Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-168-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-228-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
EDGAR
2026-08-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-018-K3.02 — Unregistered Sales of Equity Securities
3.03 — Material Modification to Rights of Security Holders
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-018-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2025-08-128-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2024-10-178-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2024-07-168-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
EDGAR
2024-03-298-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2024-03-148-K1.01 — Entry into a Material Definitive AgreementEDGAR

Registration filings — Eloxx Pharmaceuticals, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ELOX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs